Trastuzumab: A Picky Partner?MCARTHUR, Heather L; HUDIS, Clifford A.Clinical cancer research (Print). 2009, Vol 15, Num 20, pp 6311-6313, issn 1078-0432, 3 p.Article

Preclinical characterisation of ¹¹¹In-DTPA-trastuzumabLUB-DE HOOGE, Marjolijn N; KOSTERINK, Jos G. W; PERIK, Patrick J et al.British journal of pharmacology. 2004, Vol 143, Num 1, pp 99-106, issn 0007-1188, 8 p.Article

Maximizing clinical benefit with trastuzumabBELL, Richard; VERMA, Shail; UNTCH, Michael et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 35-44, issn 0093-7754, 10 p., SUP10Article

❹ Trastuzumab emtansine (T-DM1) Dans les yeux d'EMILIA..LAUNAY-VACHER, Vincent.Onko +. 2012, Vol 4, Num 31, pp 157-160, issn 2101-9495, 4 p.Conference Paper

Herceptin-geldanamycin immunoconjugates: Pharmacokinetics, biodistribution, and enhanced antitumor activityMANDLER, Raya; KOBAYASHI, Hisataka; HINSON, Ella R et al.Cancer research (Baltimore). 2004, Vol 64, Num 4, pp 1460-1467, issn 0008-5472, 8 p.Article

Biological therapy of salivary duct carcinomaNASHED, M; CASASOLA, R. J.Journal of laryngology and otology. 2009, Vol 123, Num 2, pp 250-252, issn 0022-2151, 3 p.Article

Reversibility of Trastuzumab Cardiotoxicity : Is the Concept Alive and Well?EWER, Michael S; TAN-CHIU, Elizabeth; TELLI, Melinda L et al.Journal of clinical oncology. 2007, Vol 25, Num 34, pp 5532-5534, issn 0732-183X, 3 p.Article

From the trastuzumab era to new target therapies : beyond revolutionBARNI, S; PETRELLI, F; CABIDDU, M et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi1-vi4, SUP6Conference Paper

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasmaJAMIESON, David; CRESTI, Nicola; VERRILL, Mark W et al.Journal of immunological methods. 2009, Vol 345, Num 1-2, pp 106-111, issn 0022-1759, 6 p.Article

Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional studyYAVAS, G; YILDIZ, F; GULER, S et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1120-1126, issn 0923-7534, 7 p.Article

Doit-on donner un traitement systémique adjuvant pour les petites tumeurs Her2+ en 2012 ?: Bilan des dernières étudesCOEFFIC, David.Onko +. 2012, Vol 4, Num 30, pp 114-118, issn 2101-9495, 5 p.Article

Future options with trastuzumab for primary systemic and adjuvant therapyBASELGA, José; GIANNI, Luca; GEYER, Charles et al.Seminars in oncology. 2004, Vol 31, Num 5, pp 51-57, issn 0093-7754, 7 p., SUP10Article

Nanoelectrode ensembles as recognition platform for electrochemical immunosensorsPOZZI MUCELLI, S; ZAMUNER, M; TORMEN, M et al.Biosensors & bioelectronics. 2008, Vol 23, Num 12, pp 1900-1903, issn 0956-5663, 4 p.Article

Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer CellsGROHS, Brittany M; YONGQING NIU; VELDHUIS, Linda J et al.Journal of agricultural and food chemistry (Print). 2010, Vol 58, Num 18, pp 10056-10063, issn 0021-8561, 8 p.Article

Trastuzumab-Induced HepatotoxicitySRINIVASAN, Sridhar; PARSA, Venkata; LIU, Chin Y et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1497-1501, issn 1060-0280, 5 p.Article

Effect of p95HER2/611CTF on the Response to Trastuzumab and ChemotherapyPARRA-PALAU, Josep Lluís; MORANCHO, Beatriz; SERRA, Violeta et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 11, issn 0027-8874, 291.1-291.5Article

The Inhibitory Effects of Trastuzumab on Corneal Neovascu larizationGÜLER, Mete; YILMAZ, Turgut; OZERCAN, Ibrahim et al.American journal of ophthalmology. 2009, Vol 147, Num 4, pp 703-708, issn 0002-9394, 6 p.Article

Trastuzumab-related cardiotoxicity : Calling into question the concept of reversibilityTELLI, Melinda L; HUNT, Sharon A; CARBON, Robert W et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3525-3533, issn 0732-183X, 9 p.Article

Herceptin (trastuzumab) therapy during pregnancy : Association with reversible anhydramniosWATSON, William J.Obstetrics and gynecology (New York. 1953). 2005, Vol 105, Num 3, pp 642-643, issn 0029-7844, 2 p.Article

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well ToleratedLEYLAND-JONES, Brian; COLOMER, Ramon; FUKUSHIMA, Yumi et al.Journal of clinical oncology. 2010, Vol 28, Num 6, pp 960-966, issn 0732-183X, 7 p.Article

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cellsNAHTA, Rita; HUNG, Mien-Chie; ESTEVA, Francisco J et al.Cancer research (Baltimore). 2004, Vol 64, Num 7, pp 2343-2346, issn 0008-5472, 4 p.Article

Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise TrainingHAYKOWSKY, Mark J; MACKEY, John R; THOMPSON, Richard B et al.Clinical cancer research (Print). 2009, Vol 15, Num 15, pp 4963-4967, issn 1078-0432, 5 p.Article

Clinical cardiac tolerability of trastuzumabPEREZ, Edith A; RODEHEFFER, Richard.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 322-329, issn 0732-183X, 8 p.Article

Management of Trastuzumab-Related Cardiac DysfunctionCARVER, Joseph R.Progress in cardiovascular diseases. 2010, Vol 53, Num 2, pp 130-139, issn 0033-0620, 10 p.Article

Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?DEL MASTRO, L; BIGHIN, C; BINI, G et al.Annals of oncology. 2010, Vol 21, Num 6, pp 1376-1377, issn 0923-7534, 2 p.Article